Drug intelligence / Profile preview

QLS1103

Development stage: Phase 1
Lead developer: Qilu Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

QLS1103 is a small molecule drug developed by Qilu Pharmaceutical for the treatment of advanced malignant solid neoplasms. It acts as a PARP7 inhibitor, targeting TCDD-inducible poly [ADP-ribose] polymerase 7 (PARP7), which is implicated in cancer cell survival and proliferation. The drug is currently in Phase I clinical trials in China to evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors[2][1][5].

Other names: QLS 1103QLS1103QLS-1103

Targets

PARP7 (Poly [adp-ribose] polymerase 7)

Beyond the preview

Go deeper on QLS1103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLS1103.

Explore the full profile